As an H2A.Z acetylation reader, BRD4 mediates the onset and progression of schizophrenia, suggesting that targeting BRD4 or H2A.Z acetylation promises to be a potential treatment for schizophrenia [176]. The gene discussed is BRD4; the disease is schizophrenia.